FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2017-09-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan
hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal
cancer that expresses the RAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF)
wild-type genes, has spread from the original site of growth to another part of the body
(metastatic), resists the effects of treatment with prior cetuximab (or panitumumab) plus
irinotecan hydrochloride-based therapy, and who have failed at least one subsequent
non-anti-epidermal growth factor receptor (EGFR) containing treatment regimen. Drugs used in
chemotherapy, such as fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving more than one drug
(combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as
panitumumab, may block tumor growth in different ways by targeting certain cells. Giving
FOLFIRI together with panitumumab may be an effective treatment for colorectal cancer.